Get the Stockscreener App
14.90
1.46%
-0.22
After Hours:
14.89
-0.010
-0.07%
Fulgent Genetics Inc stock is traded at $14.90, with a volume of 872.03K.
It is down -1.46% in the last 24 hours and down -11.41% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$15.12
Open:
$14.9
24h Volume:
872.03K
Relative Volume:
1.51
Market Cap:
$423.17M
Revenue:
$320.35M
Net Income/Loss:
$-75.01M
P/E Ratio:
-6.2205
EPS:
-2.3953
Net Cash Flow:
$-113.17M
1W Performance:
-2.61%
1M Performance:
-11.41%
6M Performance:
-34.59%
1Y Performance:
-23.82%
1-Day Range:
$14.54
$15.23
1-Week Range:
$14.04
$15.50
52-Week Range:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
14.90 | 429.42M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Australia
Fulgent Genetics (FLGT) Trailing US$60 Million Loss Tests Bullish Margin Narratives - Sahm
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Na - GuruFocus
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
Fulgent Genetics, Inc. Q1 2026 SEC 10-Q Filing: Financial Statements, Company Information, and Risk Disclosure - Minichart
Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Is Fulgent Genetics (FLGT) 38.5% Undervalued After Q1 2026? Reve - GuruFocus
Fulgent outlines $350M 2026 revenue outlook following Bako/StrataDx acquisition - MSN
Fulgent (FLGT) Q1 2026 Earnings Transcript - AOL.com
Fulgent Genetics, Inc. (FLGT) reports Q1 loss, beats revenue estimates - MSN
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulgent Genetics Posts Q1 Loss, Reaffirms 2026 Outlook - TipRanks
Fulgent Genetics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results By Investing.com - Investing.com South Africa
Fulgent Reports First Quarter 2026 Financial Results - BioSpace
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results - Investing.com
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call - Benzinga
Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat - ChartMill
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance - MarketBeat
FULGENT GENETICS ($FLGT) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Fulgent Genetics, Inc. Quarterly Earnings Report - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) posts Q1 2026 loss, reaffirms $350M revenue outlook - Stock Titan
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Fulgent Genetics Q1 2026 earnings preview - MSN
Fulgent Genetics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Fulgent Genetics (FLGT) CSO has 1,645 shares withheld for tax obligations - Stock Titan
Fulgent Genetics (FLGT) COO reports tax-withholding share disposition after RSU vesting - Stock Titan
Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes - Stock Titan
Fulgent Reports Second Quarter 2024 Financial Results - 富途牛牛
Fulgent Genetics rises on earnings, revenue beat - MSN
Fulgent Genetics (FLGT) to Release Earnings on Friday - MarketBeat
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting - BioSpace
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Analysts - MarketBeat
Fulgent Genetics to present nano-encapsulated anti-tumor drug FID-007 efficacy at ASCO meeting - Traders Union
Head and neck cancer study from Fulgent gets ASCO oral slot - Stock Titan
Fulgent Genetics (FLGT) Stock Pre Market (Momentum Building) 2026-04-18Top Picks - Cổng thông tin điện tử Tỉnh Sơn La
Fulgent Genetics Under Investigation for Securities Law Violations - Intellectia AI
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - lincolnjournal.com
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026 - BioSpace
Press Release: Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026 - Moomoo
Stock Recap: Whats the analyst consensus on Fulgent Genetics Inc2026 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Pullback Watch: Is Fulgent Genetics Inc a momentum stock2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
Stop Loss: Can Fulgent Genetics Inc stock outperform in a bear market2026 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Fulgent Genetics Inc (FLGT) Stock Down 3.9% -- Now Undervalued? GF Score: 64/100 - GuruFocus
Precision Trading with Fulgent Genetics Inc. (FLGT) Risk Zones - Stock Traders Daily
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):